Rutkowski P - Search Results

1

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.

Gronchi A, Bonvalot S, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom HJ, van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Broto JM, Wardelmann E, Marréaud S, Smithers M, Le Cesne A, Zaffaroni F, Litière S, Blay JY, Casali PG. Gronchi A, et al. Among authors: rutkowski p. JAMA Surg. 2020 Jun 1;155(6):e200397. doi: 10.1001/jamasurg.2020.0397. Epub 2020 Jun 17. JAMA Surg. 2020. PMID: 32236507 Free PMC article. Clinical Trial.

2

The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).

Rutkowski P, Nyckowski P, Grzesiakowska U, Nowecki ZI, Nasierowska-Guttmejer A, Pienkowski A, Dudek K, Krawczyk M, Ruka W. Rutkowski P, et al. Neoplasma. 2003;50(6):438-42. Neoplasma. 2003. PMID: 14689066

3

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.

Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M, Ruka W. Rutkowski P, et al. J Surg Oncol. 2006 Mar 15;93(4):304-11. doi: 10.1002/jso.20466. J Surg Oncol. 2006. PMID: 16496358

4

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).

Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W. Rutkowski P, et al. J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. doi: 10.1007/s00432-007-0202-4. Epub 2007 Apr 26. J Cancer Res Clin Oncol. 2007. PMID: 17458563

5

Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.

Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W. Rutkowski P, et al. Med Sci Monit. 2007 Nov;13(11):CR515-522. Med Sci Monit. 2007. PMID: 17968300

6

Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.

Woźniak A, Rutkowski P, Sciot R, Ruka W, Michej W, Debiec-Rychter M. Woźniak A, et al. Among authors: rutkowski p. Int J Cancer. 2008 May 1;122(9):2160-4. doi: 10.1002/ijc.23338. Int J Cancer. 2008. PMID: 18183595

7

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.

Ruka W, Rutkowski P, Szawłowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, Dziewirski W, Siedlecki JA, Michej W. Ruka W, et al. Among authors: rutkowski p. Eur J Surg Oncol. 2009 Jan;35(1):87-91. doi: 10.1016/j.ejso.2008.01.003. Epub 2008 Mar 4. Eur J Surg Oncol. 2009. PMID: 18289826

8

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Rutkowski P, et al. J Clin Oncol. 2010 Apr 1;28(10):1772-9. doi: 10.1200/JCO.2009.25.7899. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194851 Free PMC article.

9

Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.

Rutkowski P, Wozniak A, Dębiec-Rychter M, Kąkol M, Dziewirski W, Zdzienicki M, Ptaszynski K, Jurkowska M, Limon J, Siedlecki JA. Rutkowski P, et al. Cancer. 2011 Nov 1;117(21):4916-24. doi: 10.1002/cncr.26079. Epub 2011 Mar 31. Cancer. 2011. PMID: 21456019 Free article.

10

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.

Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wroński M, Głuszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H. Rutkowski P, et al. Eur J Surg Oncol. 2011 Oct;37(10):890-6. doi: 10.1016/j.ejso.2011.06.005. Epub 2011 Jul 7. Eur J Surg Oncol. 2011. PMID: 21737227

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

692 results

Search Page

Filters